– USA, NC – Bryn Pharma LLC, a pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced the appointments of Sandy Loreaux and Bill Humphries to its Board of Directors.
“Sandy and Bill bring decades of experience and strong commercialization skill sets to our Board. With the completion of the UTULY clinical program, we look forward to working with Sandy and Bill to plan for the U.S. market launch,” said Board Chairman, Steve Hartman.
CEO, Dr. David Dworaczyk added, “Sandy and Bill’s appointments bring deep commercial expertise to Bryn that will help us navigate the transition from an R&D organization to a fully integrated commercial organization. They are joining Bryn’s board at a critical time and we are thrilled to welcome them to our team.”
About Sandy Loreaux
Ms. Loreaux has over 25 years of experience in the pharmaceutical industry. She currently leads Covis Pharma’s U.S. Operations as U.S. President. Sandy joined Covis in November 2021 after serving as SVP and GM, of U.S. Critical Care for Mallinckrodt Pharmaceuticals. She has led multiple market access initiatives in her roles as SVP, Head of Market Access at Mallinckrodt Pharmaceuticals and SVP, Head of Market Access, and Commercial Operations at Bausch Health. Ms. Loreaux spent the first 19 years of her career at Sanofi and its legacy companies in various roles of increasing responsibility across medical affairs, sales, marketing, and market access.
Ms. Loreaux is a pharmacist by training and has a degree from Temple University School of Pharmacy in Philadelphia. As a mother of children who were diagnosed with life-threatening food allergies as infants, Ms. Loreaux brings a personal passion and commitment to bringing epinephrine delivery alternatives to market.
About William D. Humphries
Bill Humphries has more than 30 years of experience building and leading commercial-stage pharmaceutical organizations. He is currently CEO of Isosceles Pharmaceuticals, a position he has held since May 2021. Previously, Mr. Humphries served as President of Ortho Dermatologics, a Bausch Health Company. Before joining Ortho Dermatologics, he served as President and CEO of the North American business of Merz, an affiliate of Merz Pharma Group, where he oversaw strategic direction and collaboration among three North American companies: Merz Pharmaceuticals LLC, Merz Aesthetics Inc., and Merz Pharma Canada Ltd. Before joining Merz, he served in several leadership positions with Stiefel Laboratories, including CCO and President, where he spearheaded two significant acquisitions and led the global integration of Stiefel into GlaxoSmithKline. Earlier in his career, Mr. Humphries served in executive roles in sales and marketing, business development, and international marketing for Allergan, concluding as VP of its U.S. skincare business.
About Bryn Pharma
Bryn Pharma, established in 2017, is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction.
For more information: https://www.brynpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.